168 related articles for article (PubMed ID: 35884466)
1. Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors-A Retrospective Multi-Center Registry Analysis.
Koehler VF; Adam P; Fuss CT; Jiang L; Berg E; Frank-Raue K; Raue F; Hoster E; Knösel T; Schildhaus HU; Negele T; Siebolts U; Lorenz K; Allelein S; Schott M; Spitzweg C; Kroiss M;
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884466
[TBL] [Abstract][Full Text] [Related]
2. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
3. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
4. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
5. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer.
Parikh R; Hess LM; Esterberg E; Bhandari NR; Kaye JA
Thyroid Res; 2022 Feb; 15(1):2. PubMed ID: 35151352
[TBL] [Abstract][Full Text] [Related]
7. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
Schlumberger M; Elisei R; Müller S; Schöffski P; Brose M; Shah M; Licitra L; Krajewska J; Kreissl MC; Niederle B; Cohen EEW; Wirth L; Ali H; Clary DO; Yaron Y; Mangeshkar M; Ball D; Nelkin B; Sherman S
Ann Oncol; 2017 Nov; 28(11):2813-2819. PubMed ID: 29045520
[TBL] [Abstract][Full Text] [Related]
8. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
9. Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the
Sahakian N; Castinetti F; Romanet P
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835559
[TBL] [Abstract][Full Text] [Related]
10. Variability in Medullary Thyroid Carcinoma in
Mathiesen JS; Nielsen SG; Rasmussen ÅK; Kiss K; Wadt K; Hermann AP; Nielsen MF; Larsen SR; Brusgaard K; Frederiksen AL; Godballe C; Rossing M
Front Endocrinol (Lausanne); 2020; 11():251. PubMed ID: 32411094
[No Abstract] [Full Text] [Related]
11. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
12. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.
Ruiz A; Antiñolo G; Fernández RM; Eng C; Marcos I; Borrego S
Clin Endocrinol (Oxf); 2001 Sep; 55(3):399-402. PubMed ID: 11589684
[TBL] [Abstract][Full Text] [Related]
13. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
15. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
17. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
18. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib in progressive medullary thyroid cancer.
Elisei R; Schlumberger MJ; Müller SP; Schöffski P; Brose MS; Shah MH; Licitra L; Jarzab B; Medvedev V; Kreissl MC; Niederle B; Cohen EE; Wirth LJ; Ali H; Hessel C; Yaron Y; Ball D; Nelkin B; Sherman SI
J Clin Oncol; 2013 Oct; 31(29):3639-46. PubMed ID: 24002501
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]